ORYZF News and Press, Oryzon Genomics S.A. From 11/21/23

Funding provided by Nice & Green SA, a Swiss private investor This CB Program supersedes the previous one To extend its cash runway and continue the ongoing clinical trials in CNS and oncology Initial execution of €8 million in two tranches of €4 million ...

Company on track to report top line data milestone in 1Q 2024 A total of 210 participants have been recruited Multiple primary endpoints include reduction in agitation and aggression and overall BPD disease improvement MADRID, Spain and BOSTON, Nov. 07, 2023 (GLOBE NEW...

BIO-Europe 2023 LSX Investival Showcase 2023 Jefferies London Healthcare Conference 2023 MADRID, Spain and BOSTON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to d...

2023-10-27 14:26:11 ET More on Oryzon Genomics S.A. Historical earnings data for Oryzon Genomics S.A. Financial information for Oryzon Genomics S.A. For further details see: Oryzon Genomics S.A. GAAP EPS of -$0.02

Positive aggregate safety data from vafidemstat's fully enrolled PORTICO Phase IIb trial in Borderline Personality Disorder (BPD), consistent with safety data from seven completed clinical trials, supporting the drug is safe and well-tolerated Continues to enroll patients in Phase IIb EVO...

At the 36th European College of Neuropsychopharmacology congress (ECNP-2023) MADRID, Spain and BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseas...

Two collaborative projects with public research centers with a global budget of 2.3 million euros Oryzon to receive up to 1.4 million euros Focused on the discovery and validation of novel biomarkers and epigenetic targets for the treatment of neuronal pathologies MADR...

East-West Biopharma Summit 36th European College of Neuropsychopharmacology congress (ECNP 2023) Investor Access 2023 Event Jefferies Inaugural Biotech CNS/Neuro Summit Roth Capital Partners 2 nd Healthcare Opportunities Conference ESMO (Eur...

H.C. Wainwright Global Investment Conference in NYC Sachs Annual Biotech in Europe Forum in Basel Third Annual Global CMT Research Convention in Boston BioSpain-2023 in Barcelona MADRID, Spain and BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (IS...

Full recruitment secures the target number of completer patients Multiple primary endpoints include reduction in agitation and aggression and overall disease improvement Topline efficacy data expected in Q1 2024 Recent predefined Interim Analysis qualified PORTICO as non...